Skip to main content

Advertisement

SpringerLink
Log in

Oral Corticosteroids for Skin Disease in the Older Population: Minimizing Potential Adverse Effects

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Corticosteroids play a crucial role as anti-inflammatory and immunomodulatory agents in dermatology and other medical specialties; however, their therapeutic benefits are accompanied by significant risks, especially in older adults. This review examines the broad spectrum of adverse effects (AEs) associated with oral corticosteroid therapy and offers strategies to prevent, monitor, and manage these issues effectively in older adults. AEs associated with systemic corticosteroids include immune suppression, gastrointestinal problems, hyperglycemia, insulin resistance, weight gain, cardiovascular complications, ocular issues, osteoporosis, osteonecrosis, muscle weakness, collagen impairment, psychiatric symptoms, and adrenal suppression. To minimize these AEs, tailored dosing and duration, frequent monitoring, and additional preventative measures can be employed to optimize corticosteroid treatment. By customizing management plans to the specific needs and risk factors associated with each patient, clinicians can promote the safe and effective use of oral corticosteroids, ultimately improving outcomes and quality of life in patients with inflammatory dermatologic disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(5234):286–90. https://doi.org/10.1126/science.270.5234.286.

    Article  CAS  PubMed  Google Scholar 

  2. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. https://doi.org/10.1186/1710-1492-9-30.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768–75. https://doi.org/10.1111/bjd.15928.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Buonavoglia A, Leone P, Dammacco R, et al. Pemphigus and mucous membrane pemphigoid: an update from diagnosis to therapy. Autoimmun Rev. 2019;18(4):349–58. https://doi.org/10.1016/j.autrev.2019.02.005.

    Article  PubMed  Google Scholar 

  5. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013;65(2):294–8. https://doi.org/10.1002/acr.21796.

    Article  PubMed  Google Scholar 

  6. Marcus MW, Müskens RP, Ramdas WD, et al. Corticosteroids and open-angle glaucoma in the elderly: a population-based cohort study. Drugs Aging. 2012;29(12):963–70. https://doi.org/10.1007/s40266-012-0029-9.

    Article  CAS  PubMed  Google Scholar 

  7. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–6. https://doi.org/10.1002/art.21984.

    Article  PubMed  Google Scholar 

  8. Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689–704. https://doi.org/10.1111/jdv.18220.

    Article  CAS  PubMed  Google Scholar 

  9. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622–8. https://doi.org/10.1016/j.jaad.2007.05.024.

    Article  PubMed  Google Scholar 

  10. Schmidt E, Sticherling M, Sárdy M, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update. J Dtsch Dermatol Ges. 2020;18(5):516–26. https://doi.org/10.1111/ddg.14097.

    Article  PubMed  Google Scholar 

  11. Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733-740.e11. https://doi.org/10.1016/j.jaad.2017.09.074.

    Article  CAS  PubMed  Google Scholar 

  12. Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016;42(1):15–vii. https://doi.org/10.1016/j.rdc.2015.08.002.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98. https://doi.org/10.2165/00003088-200544010-00003.

    Article  CAS  PubMed  Google Scholar 

  14. Kane SP. Corticosteroid Conversion Calculator. ClinCalc. Updated 24 October 2015. Available at: https://clincalc.com/Corticosteroids. Accessed 23 Feb 2024.

  15. Gom I, Fukushima H, Shiraki M, et al. Relationship between serum albumin level and aging in community-dwelling self-supported elderly population. J Nutr Sci Vitaminol (Tokyo). 2007;53(1):37–42. https://doi.org/10.3177/jnsv.53.37.

    Article  PubMed  Google Scholar 

  16. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735–40. https://doi.org/10.7326/0003-4819-114-9-735.

    Article  CAS  PubMed  Google Scholar 

  17. Tseng CL, Chen YT, Huang CJ, et al. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. Aliment Pharmacol Ther. 2015;42(5):599–606. https://doi.org/10.1111/apt.13298.

    Article  CAS  PubMed  Google Scholar 

  18. Tornatore KM, Logue G, Venuto RC, Davis PJ. Pharmacokinetics of methylprednisolone in elderly and young healthy males. J Am Geriatr Soc. 1994;42(10):1118–22. https://doi.org/10.1111/j.1532-5415.1994.tb06219.x.

    Article  CAS  PubMed  Google Scholar 

  19. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2023. Available at: https://ginasthma.org/2023-gina-main-report/. Accessed 23 Aug 2023.

  20. Bajaj JS, Wong F, Kamath PS, Lai JC, O’Leary JG. Acute-on-chronic liver failure. Am J Gastroenterol. 2022;117(6):831–4. https://doi.org/10.14309/ajg.0000000000001748.

    Article  PubMed  Google Scholar 

  21. Joly P, Roujeau JC, Benichou J, et al. Bullous Diseases French Study Group. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7. https://doi.org/10.1056/NEJMoa011592.

    Article  CAS  PubMed  Google Scholar 

  22. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–93.

    Article  PubMed  Google Scholar 

  23. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119–24. https://doi.org/10.1136/ard.2008.092163.

    Article  CAS  PubMed  Google Scholar 

  24. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–23. https://doi.org/10.1016/0002-9343(94)90131-7.

    Article  CAS  PubMed  Google Scholar 

  25. Ito SM, Yamanashi Y, Takada T, Suzuki H. Clinical importance of drug–drug interaction between warfarin and prednisolone and its potential mechanism in relation to the Niemann-Pick C1-like 1-mediated pathway. Circ J. 2019;83(2):471–80. https://doi.org/10.1253/circj.CJ-18-0807.

    Article  CAS  PubMed  Google Scholar 

  26. Smith SF. Lipocortin 1. glucocorticoids caught in the act? Thorax. 1996;51(10):1057–9. https://doi.org/10.1136/thx.51.10.1057.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13. https://doi.org/10.1016/j.mce.2010.04.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216–29. https://doi.org/10.1016/j.clinthera.2017.09.011.

    Article  CAS  PubMed  Google Scholar 

  29. Weyand CM, Goronzy JJ. Aging of the immune system. Mechanisms and therapeutic targets. Ann Am Thorac Soc. 2016;13(Suppl 5):S422–8. https://doi.org/10.1513/AnnalsATS.201602-095AW.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Fardet L, Petersen I, Nazareth I. Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med. 2016;13(5): e1002024. https://doi.org/10.1371/journal.pmed.1002024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kumar SS, Arvind S, Umpierrez AP. Things We Do for No Reason™: Routine use of proton pump inhibitors for peptic ulcer prophylaxis in adults on high-dose corticosteroids. J Hosp Med. 2023;18(7):630–2. https://doi.org/10.1002/jhm.13095.

    Article  PubMed  Google Scholar 

  32. Filaretova L, Podvigina T, Yarushkina N. Physiological and pharmacological effects of glucocorticoids on the gastrointestinal tract. Curr Pharm Des. 2020;26(25):2962–70. https://doi.org/10.2174/1381612826666200521142746.

    Article  CAS  PubMed  Google Scholar 

  33. Borum ML. Peptic-ulcer disease in the elderly. Clin Geriatr Med. 1999;15(3):457–71.

    Article  CAS  PubMed  Google Scholar 

  34. Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Intern Med. 2013;173(6):444–9. https://doi.org/10.1001/jamainternmed.2013.2737.

    Article  CAS  PubMed  Google Scholar 

  35. Derk CT, DeHoratius RJ. Systemic lupus erythematosus and acute pancreatitis: a case series. Clin Rheumatol. 2004;23(2):147–51. https://doi.org/10.1007/s10067-003-0793-3.

    Article  PubMed  Google Scholar 

  36. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073–81. https://doi.org/10.4239/wjd.v6.i8.1073.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Markovič R, Grubelnik V, Vošner HB, et al. Age-related changes in lipid and glucose levels associated with drug use and mortality: an observational study. J Pers Med. 2022;12(2):280. https://doi.org/10.3390/jpm12020280.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Head T, Daunert S, Goldschmidt-Clermont PJ. The aging risk and atherosclerosis: a fresh look at arterial homeostasis. Front Genet. 2017;8:216. https://doi.org/10.3389/fgene.2017.00216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;53(4):528–35. https://doi.org/10.1002/art.21329.

    Article  CAS  PubMed  Google Scholar 

  40. Atik N, Hayati RU, Hamijoyo L. Correlation between steroid therapy and lipid profile in systemic lupus erythematosus patients. Open Access Rheumatol. 2020;12:41–6. https://doi.org/10.2147/OARRR.S245662.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Svenson KL, Lithell H, Hällgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med. 1987;147(11):1917–20.

    Article  CAS  PubMed  Google Scholar 

  42. National Heart Lung and Blood Institute. Diagnosis. Available at: https://www.nhlbi.nih.gov/health/blood-cholesterol/diagnosis#:~:text=Screening%20may%20be%20performed%20as,every%201%20to%202%20years. Accessed 15 Apr 2024.

  43. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314(10):1021–9. https://doi.org/10.1001/jama.2015.10029.

    Article  CAS  PubMed  Google Scholar 

  44. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154(1):97–101.

    Article  CAS  PubMed  Google Scholar 

  45. Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96–102. https://doi.org/10.1002/dmrr.2486.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation. 1991;51(2):374–7. https://doi.org/10.1097/00007890-199102000-00020.

    Article  CAS  PubMed  Google Scholar 

  47. Leung E, Wongrakpanich S, Munshi MN. Diabetes management in the elderly. Diabetes Spectr. 2018;31(3):245–53. https://doi.org/10.2337/ds18-0033.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Bini J, Parikh L, Lacadie C, et al. Stress-level glucocorticoids increase fasting hunger and decrease cerebral blood flow in regions regulating eating. Neuroimage Clin. 2022;36: 103202. https://doi.org/10.1016/j.nicl.2022.103202.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Fardet L, Cabane J, Lebbé C, Morel P, Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. 2007;57:604–9. https://doi.org/10.1016/j.jaad.2007.04.018.

    Article  PubMed  Google Scholar 

  50. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007;157(1):142–8. https://doi.org/10.1111/j.1365-2133.2007.07950.x.

    Article  CAS  PubMed  Google Scholar 

  51. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A. Endocrine society. Treatment of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. So H, Lam TO, Meng H, Lam SHM, Tam LS. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82(11):1387–93. https://doi.org/10.1136/ard-2023-224185.

    Article  CAS  PubMed  Google Scholar 

  53. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357: j2099. https://doi.org/10.1136/bmj.j2099.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Mu X, Wu A, Hu H, Zhou H, Yang M. Assessment of QRISK3 as a predictor of cardiovascular disease events in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:1077632.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Rippe JM. Lifestyle strategies for risk factor reduction, prevention, and treatment of cardiovascular disease. Am J Lifestyle Med. 2018;13(2):204–12. https://doi.org/10.1177/1559827618812395.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022;399(10338):1876–85. https://doi.org/10.1016/S0140-6736(22)00122-2.

    Article  CAS  PubMed  Google Scholar 

  57. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31(5):1213–24. https://doi.org/10.1038/ki.1987.131.

    Article  CAS  PubMed  Google Scholar 

  58. Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Lond). 1981;61(Suppl 7):381s–3s. https://doi.org/10.1042/cs061381s.

    Article  CAS  PubMed  Google Scholar 

  59. Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ. 2020;192(12):E295–301. https://doi.org/10.1503/cmaj.191012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Grünfeld JP, Eloy L, Moura AM, Ganeval D, Ramos-Frendo B, Worcel M. Effects of antiglucocorticoids on glucocorticoid hypertension in the rat. Hypertension. 1985;7(2):292–9. https://doi.org/10.1161/01.hyp.7.2.292.

    Article  PubMed  Google Scholar 

  61. Lawes CM, Vander Hoorn S, Rodgers A. International Society of H. global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–8.

    Article  PubMed  Google Scholar 

  62. van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016–20. https://doi.org/10.1001/archinte.166.9.1016.

    Article  PubMed  Google Scholar 

  63. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009;169(18):1677–83. https://doi.org/10.1001/archinternmed.2009.297.

    Article  PubMed  Google Scholar 

  64. Üsküdar Cansu D, Bodakçi E, Korkmaz C. Dose-dependent bradycardia as a rare side effect of corticosteroids: a case report and review of the literature. Rheumatol Int. 2018;38(12):2337–43. https://doi.org/10.1007/s00296-018-4167-1.

    Article  PubMed  Google Scholar 

  65. Lieber BA, Han J, Appelboom G, et al. Association of steroid use with deep venous thrombosis and pulmonary embolism in neurosurgical patients: a national database analysis. World Neurosurg. 2016;89:126–32. https://doi.org/10.1016/j.wneu.2016.01.033.

    Article  PubMed  Google Scholar 

  66. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis. 2009;28:401–9. https://doi.org/10.1007/s11239-009-0378-3.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients [published correction appears in Blood Adv. 2023 May;7(9):1671]. Blood Adv. 2018;2(22):3198–225. https://doi.org/10.1182/bloodadvances.2018022954.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Long WF. A case of elevated intraocular pressure associated with systemic steroid therapy. Am J Optom Physiol Opt. 1977;54(4):248–52. https://doi.org/10.1097/00006324-197704000-00010.

    Article  CAS  PubMed  Google Scholar 

  69. Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep. 2021;11(1):13762. https://doi.org/10.1038/s41598-021-92971-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Wubet GM, Assefa AA. Glaucoma and its predictors among adult patients attending ophthalmic outpatient department: a hospital-based study, North West Ethiopia. BMC Ophthalmol. 2021;21(1):400. https://doi.org/10.1186/s12886-021-02168-y.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020;12(11): e11686. https://doi.org/10.7759/cureus.11686.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced Glaucoma: an avoidable irreversible blindness. J Curr Glaucoma Pract. 2017;11(2):67–72.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Mandapati JS, Metta AK. Intraocular pressure variation in patients on long-term corticosteroids. Indian Dermatol Online J. 2011;2(2):67–9. https://doi.org/10.4103/2229-5178.85993.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Schuster AK, Erb C, Hoffmann EM, et al. The diagnosis and treatment of glaucoma. Dtsch Arztebl Int. 2020;117(13):225–34. https://doi.org/10.3238/arztebl.2020.0225.

    Article  PubMed  Google Scholar 

  75. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004;111(2):244–9. https://doi.org/10.1016/j.ophtha.2003.09.024.

    Article  PubMed  Google Scholar 

  76. De Nijs E, Brabant P, De Laey JJ. The adverse effects of corticosteroids in central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 2003;289:35–41.

    Google Scholar 

  77. Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019;30(6):1145–56. https://doi.org/10.1007/s00198-019-04906-x.

    Article  CAS  PubMed  Google Scholar 

  78. Wong SPY, Mok CC. Management of glucocorticoid-related osteoporotic vertebral fracture. Osteoporos Sarcopenia. 2020;6(1):1–7. https://doi.org/10.1016/j.afos.2020.02.002.

    Article  PubMed  PubMed Central  Google Scholar 

  79. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87. https://doi.org/10.1007/s001980200108.

    Article  PubMed  Google Scholar 

  80. Adler RA. Glucocorticoid-induced osteoporosis: management challenges in older patients. J Clin Densitom. 2019;22(1):20–4. https://doi.org/10.1016/j.jocd.2018.03.004.

    Article  PubMed  Google Scholar 

  81. Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405–19. https://doi.org/10.1002/acr.25240.

    Article  CAS  PubMed  Google Scholar 

  82. Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001–2006. J Clin Endocrinol Metab. 2011;96(12):3838–45. https://doi.org/10.1210/jc.2011-1600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Kast S, Jakob F, Kohl M, et al. Exercise effects on glucocorticoid-induced bone loss in adults: a systematic review and meta-analysis. Rheumatol Adv Pract. 2023;7(1): rkad019. https://doi.org/10.1093/rap/rkad019.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10(10): CD001347. https://doi.org/10.1002/14651858.CD001347.pub2.

    Article  PubMed  Google Scholar 

  85. Carpinteri R, Porcelli T, Mejia C, et al. Glucocorticoid-induced osteoporosis and parathyroid hormone. J Endocrinol Invest. 2010;33(7 Suppl):16–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Shigemura T, Nakamura J, Kishida S, et al. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatology (Oxford). 2011;50(11):2023–8. https://doi.org/10.1093/rheumatology/ker277.

    Article  CAS  PubMed  Google Scholar 

  87. Xie XH, Wang XL, Yang HL, Zhao DW, Qin L. Steroid-associated osteonecrosis: epidemiology, pathophysiology, animal model, prevention, and potential treatments (an overview). J Orthop Translat. 2015;3(2):58–70. https://doi.org/10.1016/j.jot.2014.12.002.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Bergman J, Nordström A, Nordström P. Epidemiology of osteonecrosis among older adults in Sweden. Osteoporos Int. 2019;30(5):965–73. https://doi.org/10.1007/s00198-018-04826-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC. High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplasty. 2015;30(9):1506-1512.e5. https://doi.org/10.1016/j.arth.2015.03.036.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41(2):183–90. https://doi.org/10.1007/s12020-011-9580-0.

    Article  CAS  PubMed  Google Scholar 

  91. Saini A, Saifuddin A. MRI of osteonecrosis. Clin Radiol. 2004;59(12):1079–93. https://doi.org/10.1016/j.crad.2004.04.014.

    Article  CAS  PubMed  Google Scholar 

  92. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008;197(1):1–10. https://doi.org/10.1677/JOE-07-0606.

    Article  CAS  PubMed  Google Scholar 

  93. Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology. 1991;41(8):1235–9. https://doi.org/10.1212/wnl.41.8.1235.

    Article  CAS  PubMed  Google Scholar 

  94. Gupta A, Gupta Y. Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013;17(5):913–6. https://doi.org/10.4103/2230-8210.117215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Surmachevska N, Tiwari V. Corticosteroid Induced Myopathy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

  96. Smith GI, Atherton P, Reeds DN, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr. 2011;93(2):402–12. https://doi.org/10.3945/ajcn.110.005611.

    Article  CAS  PubMed  Google Scholar 

  97. Lee MK, Jeong HH, Kim MJ, Ryu H, Baek J, Lee B. Nutrients against glucocorticoid-induced muscle atrophy. Foods. 2022;11(5):687. https://doi.org/10.3390/foods11050687.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Deer RR, Hosein E, Mera A, et al. Dietary intake patterns of community-dwelling older adults after acute hospitalization. J Gerontol A Biol Sci Med Sci. 2022;77(1):140–7. https://doi.org/10.1093/gerona/glab232.

    Article  CAS  PubMed  Google Scholar 

  99. Haapasaari K, Rossi O, Risteli J, Oikarinen A. Effects of long-term inhaled corticosteroids on skin collagen synthesis and thickness in asthmatic patients. Eur Respir J. 1998;11(1):139–43. https://doi.org/10.1183/09031936.98.11010139.

    Article  CAS  PubMed  Google Scholar 

  100. Cohen IK, Diegelmann RF, Johnson ML. Effect of corticosteroids on collagen synthesis. Surgery. 1977;82(1):15–20.

    CAS  PubMed  Google Scholar 

  101. Dyer JM, Miller RA. Chronic skin fragility of aging: current concepts in the pathogenesis, recognition, and management of dermatoporosis. J Clin Aesthet Dermatol. 2018;11(1):13–8.

    PubMed  PubMed Central  Google Scholar 

  102. James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23(5):403–20. https://doi.org/10.1089/jop.2006.0067.

    Article  CAS  PubMed  Google Scholar 

  103. Mencucci R, Stefanini S, Favuzza E, Cennamo M, De Vitto C, Mossello E. Beyond vision: cataract and health status in old age, a narrative review. Front Med (Lausanne). 2023;10:1110383. https://doi.org/10.3389/fmed.2023.1110383.

    Article  PubMed  Google Scholar 

  104. Halpern AA, Horowitz BG, Nagel DA. Tendon ruptures associated with corticosteroid therapy. West J Med. 1977;127(5):378–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  105. Kwan KYC, Ng KWK, Rao Y, et al. Effect of aging on tendon biology, biomechanics and implications for treatment approaches. Int J Mol Sci. 2023;24(20):15183. https://doi.org/10.3390/ijms242015183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Krugers HJ, Karst H, Joels M. Interactions between noradrenaline and corticosteroids in the brain: from electrical activity to cognitive performance. Front Cell Neurosci. 2012;6:15. https://doi.org/10.3389/fncel.2012.00015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Czyrak A, Maćkowiak M, Chocyk A, Fijał K, Wedzony K. Role of glucocorticoids in the regulation of dopaminergic neurotransmission. Pol J Pharmacol. 2003;55(5):667–74.

    CAS  PubMed  Google Scholar 

  108. Schubert D, LaCorbiere M, Klier FG, Steinbach JH. The modulation of neurotransmitter synthesis by steroid hormones and insulin. Brain Res. 1980;190(1):67–79. https://doi.org/10.1016/0006-8993(80)91160-9.

    Article  CAS  PubMed  Google Scholar 

  109. Pullen R. Mental status changes with corticosteroid therapy. Nursing Made Incredibly Easy. 2021;19(1):55–6. https://doi.org/10.1097/01.NME.0000723400.84384.2b.

    Article  Google Scholar 

  110. Gjerstad JK, Lightman SL, Spiga F. Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility. Stress. 2018;21(5):403–16. https://doi.org/10.1080/10253890.2018.1470238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry. 2001;3(1):17–21. https://doi.org/10.4088/pcc.v03n0104.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Bolanos SH, Khan DA, Hanczyc M, Bauer MS, Dhanani N, Brown ES. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004;92(5):500–5. https://doi.org/10.1016/S1081-1206(10)61756-5.

    Article  PubMed  Google Scholar 

  113. Brown ES, Suppes T, Khan DA, Carmody TJ 3rd. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol. 2002;22(1):55–61. https://doi.org/10.1097/00004714-200202000-00009.

    Article  PubMed  Google Scholar 

  114. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry. 2012;169(5):491–7. https://doi.org/10.1176/appi.ajp.2011.11071009.

    Article  PubMed  Google Scholar 

  115. Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 1996;47(6):1396–402. https://doi.org/10.1212/wnl.47.6.1396.

    Article  CAS  PubMed  Google Scholar 

  116. Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology. 1988;38(10):1631–4. https://doi.org/10.1212/wnl.38.10.1631.

    Article  CAS  PubMed  Google Scholar 

  117. Dubovsky AN, Arvikar S, Stern TA, Axelrod L. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics. 2012;53(2):103–15. https://doi.org/10.1016/j.psym.2011.12.007.

    Article  CAS  PubMed  Google Scholar 

  118. Wolkowitz OM, Burke H, Epel ES, Reus VI. Glucocorticoids. Mood, memory, and mechanisms. Ann N Y Acad Sci. 2009;1179:19–40. https://doi.org/10.1111/j.1749-6632.2009.04980.x.

    Article  CAS  PubMed  Google Scholar 

  119. Kenna HA, Poon AW, de los Angeles CP, Koran LM. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011;65(6):549–60. https://doi.org/10.1111/j.1440-1819.2011.02260.x.

    Article  CAS  PubMed  Google Scholar 

  120. Manzo C, Serra-Mestres J, Castagna A, Isetta M. Behavioral, psychiatric, and cognitive adverse events in older persons treated with glucocorticoids. Medicines (Basel). 2018;5(3):82. https://doi.org/10.3390/medicines5030082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. McCarthy CE. Sleep disturbance, sleep disorders and co-morbidities in the care of the older person. Med Sci (Basel). 2021;9(2):31. https://doi.org/10.3390/medsci9020031.

    Article  CAS  Google Scholar 

  122. Born J, DeKloet ER, Wenz H, Kern W, Fehm HL. Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am J Physiol. 1991;260(2 Pt 1):E183–8. https://doi.org/10.1152/ajpendo.1991.260.2.E183.

    Article  CAS  PubMed  Google Scholar 

  123. Fehm HL, Benkowitsch R, Kern W, Fehm-Wolfsdorf G, Pauschinger P, Born J. Influences of corticosteroids, dexamethasone and hydrocortisone on sleep in humans. Neuropsychobiology. 1986;16(4):198–204. https://doi.org/10.1159/000118326.

    Article  CAS  PubMed  Google Scholar 

  124. Stone KL, Xiao Q. Impact of poor sleep on physical and mental health in older women. Sleep Med Clin. 2018;13(3):457–65. https://doi.org/10.1016/j.jsmc.2018.04.012.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Kato T, Okawa G, Tanaka KF, Mitsukura Y. Dexamethasone induces sleep disturbance in a dose-dependent manner in mice. PLoS One. 2023;18(12): e0296028. https://doi.org/10.1371/journal.pone.0296028.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992;326(4):226–30. https://doi.org/10.1056/NEJM199201233260403.

    Article  CAS  PubMed  Google Scholar 

  127. Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(6):2171–80. https://doi.org/10.1210/jc.2015-1218.

    Article  CAS  PubMed  Google Scholar 

  128. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7. https://doi.org/10.1056/NEJMoa011592.

    Article  CAS  PubMed  Google Scholar 

  129. Arcana RI, Crișan-Dabija R, Cernomaz AT, et al. The risk of sarcoidosis misdiagnosis and the harmful effect of corticosteroids when the disease picture is incomplete. Biomedicines. 2023;11(1):175. https://doi.org/10.3390/biomedicines11010175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Erlendsson AM, Lönndahl L, Killasli H. Intermittent low-dose corticosteroid therapy for hidradenitis suppurativa: a case series. JAAD Case Rep. 2021;13:105–8. https://doi.org/10.1016/j.jdcr.2021.05.023.

    Article  PubMed  PubMed Central  Google Scholar 

  131. Cadet MJ. Antiretroviral therapies and corticosteroids: drug–drug interactions. Nurse Pract. 2021;46(12):40–7. https://doi.org/10.1097/01.NPR.0000798224.30305.d1.

    Article  PubMed  Google Scholar 

  132. Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother. 2006;40(12):2101–6. https://doi.org/10.1345/aph.1H418.

    Article  CAS  PubMed  Google Scholar 

  133. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061–75. https://doi.org/10.2147/TCRM.S79135.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Widmer P, Maibach R, Künzi UP, et al. Diuretic-related hypokalaemia: the role of diuretics, potassium supplements, glucocorticoids and beta 2-adrenoceptor agonists. Results from the comprehensive hospital drug monitoring programme, berne (CHDM). Eur J Clin Pharmacol. 1995;49(1–2):31–6. https://doi.org/10.1007/BF00192355.

    Article  CAS  PubMed  Google Scholar 

  135. Zhang YY, Yang L. Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications. Expert Opin Drug Metab Toxicol. 2009;5(6):621–9. https://doi.org/10.1517/17425250902967648.

    Article  CAS  PubMed  Google Scholar 

  136. Wellbutrin (bupropion hydrochloride) US prescribing information. GlaxoSmithKline November, 2019.2.Zyban (bupropion hydrochloride) US prescribing information. GlaxoSmithKline; 2019.

Download references

Author information

Authors and Affiliations

  1. University of Arizona, College of Medicine – Phoenix, 475 N 5th St, Phoenix, AZ, 85004, USA

    Kennedy Sparling

  2. University of Arizona, College of Medicine – Tucson, Tucson, AZ, USA

    Daniel C. Butler

Authors
  1. Kennedy Sparling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel C. Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kennedy Sparling.

Ethics declarations

Conflicts of Interest

Daniel C. Butler is a consultant for Galderma and Sanofi. Kennedy Sparling has no conflicts of interest to declare that may be relevant to the contents of this article.

Ethical Approval

Not applicable.

Patient Consent to Participate/Publish

Not applicable.

Funding

No sources of funding were received to assist in the preparation of this article.

Data and Code Availability

Not applicable.

Authors’ Contributions

KS: writing—original draft preparation, writing—review and editing. DCB: conceptualization, validation, review and editing. Both authors read and approved the final version of the manuscript.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sparling, K., Butler, D.C. Oral Corticosteroids for Skin Disease in the Older Population: Minimizing Potential Adverse Effects. Drugs Aging (2024). https://doi.org/10.1007/s40266-024-01143-8

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40266-024-01143-8

Search

Navigation